Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease
Portfolio Pulse from Vandana Singh
Regulus Therapeutics Inc (NASDAQ:RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The drug was well tolerated with no safety findings and showed increases in disease-related urinary biomarkers. Data from the second cohort, dosed at 2mg/kg, are anticipated in the first quarter of 2024. RGLS shares are down 10.90% at $1.47 on the last check Wednesday.
September 20, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regulus Therapeutics released positive Phase 1b trial results for its drug RGLS8429, which is being tested for ADPKD. Despite the positive news, the company's shares fell by 10.90%.
The positive results from the Phase 1b trial of RGLS8429 indicate that the drug is well tolerated and shows promising efficacy, which could potentially lead to future revenue for the company. However, despite this positive news, the company's stock price fell by 10.90%, indicating that the market may have expected more from the trial results or that other factors are influencing the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100